Celyad Oncology SA Stock OTC Markets
Equities
CYADY
US1512052002
Biotechnology & Medical Research
Sales 2022 | - | Sales 2023 | 102K 111K 151K | Capitalization | 16.16M 17.56M 23.89M |
---|---|---|---|---|---|
Net income 2022 | -40M -43.47M -59.15M | Net income 2023 | -8M -8.69M -11.83M | EV / Sales 2022 | - |
Net cash position 2022 | 12.19M 13.25M 18.03M | Net cash position 2023 | 5.95M 6.46M 8.79M | EV / Sales 2023 | 100 x |
P/E ratio 2022 |
-0.28
x | P/E ratio 2023 |
-1.19
x | Employees | 18 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.37% |
Latest transcript on Celyad Oncology SA
Managers | Title | Age | Since |
---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
David Georges
DFI | Director of Finance/CFO | - | 18-12-31 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
Hilde Windels
CHM | Chairman | 59 | 18-05-06 |
Serge Goblet
BRD | Director/Board Member | - | 07-12-31 |
1st Jan change | Capi. | |
---|---|---|
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |